Core Insights - Boston Scientific Corp. shares increased over 4% in intra-day trading following the release of third-quarter earnings and revenue that surpassed analyst expectations, driven by strong performance across all business segments [1] Financial Performance - The company reported adjusted earnings per share (EPS) of $0.75, exceeding the consensus estimate of $0.71 [2] - Revenue grew 20.3% year-over-year to $5.07 billion, surpassing forecasts of $4.97 billion [2] - Organic revenue increased by 15.3%, exceeding the company's previous guidance range of 12% to 14% [2] Segment Performance - The Cardiovascular segment experienced significant growth, with revenue up 22.4% [2] - The MedSurg segment also showed strong performance, climbing 16.4% [2] - U.S. sales increased by 27% compared to the same quarter last year, indicating robust domestic demand [2] Future Outlook - Boston Scientific raised its full-year 2025 outlook, now anticipating adjusted EPS between $3.02 and $3.04, compared to the consensus of $2.98 [3] - For the fourth quarter, management guided for EPS between $0.77 and $0.79, above the Wall Street forecast of $0.76 [3]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

医疗器械公司波士顿科学(BSX.US)涨超4.4%，报104.36美元。 消息面上，波士顿科学第三季度销售额同比增长20%至50.7亿美元，超出华尔街分析师预期的49.7亿美 元。其中，心血管部门的销售额同比增长22%至33.4亿美元，高于预期的32.7亿美元。期内调整后每股 收益为75美分，高于预期的71美分。公司上调全年调整后每股收益指引至3.02至3.04美元，超过分析师 预期的2.98美元。(格隆汇) ...

Key Takeaways Boston Scientific's Q3 EPS rose 19% to $0.75, topping estimates and guidance. BSX's quarterly revenues climbed 20.3% to $5.07B, led by strength in Cardiovascular and MedSurgBoston Scientific raised 2025 sales growth to 20% and EPS outlook to $3.02-$3.04. Boston Scientific Corporation (BSX) posted third-quarter 2025 adjusted earnings per share (EPS) of 75 cents, up 19% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 5.6% and exceeded the company’s adjusted EPS guidance ...

格隆汇10月22日｜医疗器械公司波士顿科学公布第三季度业绩，销售额同比增长20%至50.7亿美元，超 出华尔街分析师预期的49.7亿美元。其中，心血管部门的销售额同比增长22%至33.4亿美元，高于预期 的32.7亿美元。期内调整后每股收益为75美分，高于预期的71美分。 展望第四季度，公司预计每股收益将介于77至79美分之间，分析师预期为76美分。对于今年全年，公司 将调整后每股收益指引从2.95至2.99美元上调至3.02至3.04美元，分析师预期为2.98美元。 ...

Boston Scientific (NYSE:BSX) Q3 2025 Earnings Call October 22, 2025 08:00 AM ET Company ParticipantsMike Mahoney - Chairman and CEODavid Roman - Managing DirectorPatrick Wood - Managing DirectorJon Monson - EVP and CFOJoanne Wuensch - Managing DirectorLauren Tengler - VP of Investor RelationsKen Stein - CMORick Wise - Managing DirectorConference Call ParticipantsPito Chickering - AnalystTravis Steed - Managing Director and Equity Research AnalystVijay Kumar - Senior Managing Director and Equity Research Ana ...

Boston Scientific (NYSE:BSX) Q3 2025 Earnings Call October 22, 2025 08:00 AM ET Company ParticipantsMike Mahoney - Chairman and CEODavid Roman - Managing DirectorPatrick Wood - Managing DirectorJon Monson - EVP and CFOJoanne Wuensch - Managing DirectorLauren Tengler - VP of Investor RelationsKen Stein - CMORick Wise - Managing DirectorConference Call ParticipantsPito Chickering - AnalystTravis Steed - Managing Director and Equity Research AnalystVijay Kumar - Senior Managing Director and Equity Research Ana ...

Boston Scientific (NYSE:BSX) Q3 2025 Earnings Call October 22, 2025 08:00 AM ET Speaker4Good morning and welcome to the Boston Scientific Third Quarter 2025 earnings call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing star then zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, ...

Boston Scientific (NYSE:BSX) Q3 2025 Earnings Call October 22, 2025 08:00 AM ET Speaker0Good morning, and welcome to the Boston Scientific Third Quarter twenty twenty five Earnings Call. All participants will be in listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Lauren Tangler, Vice President, Investor Relations. Please go ahead.Speaker1Thank you, Drew, and thanks to everyone for joining us. With me today are Mike Mahoney, Chairman and Chief Execut ...

BREAKING: Gold Prices, Stocks Continue To SlideBoston Scientific (BSX) stock rose early Wednesday after the medical products giant reported adjusted earnings of 75 cents per share on $5.07 billion in third-quarter sales.On average, analysts polled by FactSet expected Boston Sci to earn 71 cents per share and report $4.97 billion in sales.During the year-earlier period, the company earned 63 cents a share and had $4.21 billion in sales.For the year, Boston Scientific guided to 20% sales growth on a strict, a ...